

# Oliver Fitzgerald Mb Bch Bao, Mrcpi, M

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5557730/publications.pdf>

Version: 2024-02-01

280  
papers

18,534  
citations

13865

67  
h-index

15732

125  
g-index

301  
all docs

301  
docs citations

301  
times ranked

16024  
citing authors

#	ARTICLE	IF	CITATIONS
1	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	21.4	918
2	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	21.4	848
3	Synovial tissue inflammation in early and late osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1263-1267.	0.9	779
4	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
5	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
6	Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 115-124.	6.7	453
7	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017, 377, 1537-1550.	27.0	434
8	Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1045-1050.	0.9	424
9	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397
10	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. <i>Nature Genetics</i> , 2010, 42, 996-999.	21.4	334
11	Inequities in access to biologic and synthetic DMARDs across 46 European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 198-206.	0.9	289
12	Comparison of the accuracy of steroid placement with clinical outcome in patients with shoulder symptoms. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 59-63.	0.9	272
13	High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 736-740.	0.9	248
14	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.9	240
15	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 319-326.	0.9	234
16	Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. <i>European Journal of Immunology</i> , 2005, 35, 1347-1359.	2.9	232
17	Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 893-900.	6.7	230
18	Th17 and Th22 cells in psoriatic arthritis and psoriasis. <i>Arthritis Research and Therapy</i> , 2013, 15, R136.	3.5	212

#	ARTICLE	IF	CITATIONS
19	Synovial tissue hypoxia and inflammation in vivo. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1389-1395.	0.9	198
20	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
21	HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. <i>Arthritis and Rheumatism</i> , 2012, 64, 1134-1144.	6.7	187
22	Development of a preliminary composite disease activity index in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 272-277.	0.9	184
23	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1550-1558.	0.9	184
24	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	8.0	182
25	Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2014, 371, 1781-1792.	27.0	169
26	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1167-70.	2.0	155
27	Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor- $\alpha$ , Oncostatin M and response to biologic therapies. <i>Arthritis Research and Therapy</i> , 2009, 11, R113.	3.5	150
28	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046.	12.8	149
29	Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. <i>Arthritis Research and Therapy</i> , 2015, 17, 115.	3.5	147
30	Cytokine gene polymorphisms: Association with psoriatic arthritis susceptibility and severity. <i>Arthritis and Rheumatism</i> , 2003, 48, 1408-1413.	6.7	136
31	Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1788-1799.	6.7	136
32	High Prevalence of Metabolic Syndrome and of Insulin Resistance in Psoriatic Arthritis is Associated with the Severity of Underlying Disease. <i>Journal of Rheumatology</i> , 2014, 41, 1357-1365.	2.0	135
33	Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF- $\kappa$ B-dependent signal transduction pathway. <i>Arthritis and Rheumatism</i> , 2006, 54, 105-114.	6.7	134
34	Suprascapular nerve block (using bupivacaine and methylprednisolone acetate) in chronic shoulder pain. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 400-406.	0.9	129
35	Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. <i>Arthritis Research</i> , 2000, 2, 142.	2.0	122
36	Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 394-399.	0.9	121

#	ARTICLE	IF	CITATIONS
37	Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2263-2274.	6.7	120
38	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 291-304.	3.4	119
39	Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1386-1394.	2.0	114
40	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	30.5	113
41	Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. <i>Arthritis and Rheumatism</i> , 1998, 41, 663-669.	6.7	110
42	Psoriatic arthritis: from pathogenesis to therapy. <i>Arthritis Research and Therapy</i> , 2009, 11, 214.	3.5	110
43	Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1991, 50, 792-796.	0.9	108
44	Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1676-1685.	6.7	108
45	A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1990-1995.	0.9	108
46	Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 1744-1753.	6.7	107
47	Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers. <i>Journal of Rheumatology</i> , 2009, 36, 1800-1802.	2.0	107
48	Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 1003-1012.	1.2	105
49	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1641-1644.	0.9	103
50	Activation of Nuclear Orphan Receptor NURR1 Transcription by NF- $\kappa$ B and Cyclic Adenosine 5'-Monophosphate Response Element-Binding Protein in Rheumatoid Arthritis Synovial Tissue. <i>Journal of Immunology</i> , 2002, 168, 2979-2987.	0.8	102
51	Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 155-162.	0.9	100
52	Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. <i>Rheumatology</i> , 1999, 38, 34-42.	1.9	97
53	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
54	Acute Serum Amyloid A Induces Migration, Angiogenesis, and Inflammation in Synovial Cells In Vitro and in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model. <i>Journal of Immunology</i> , 2010, 184, 6427-6437.	0.8	92

#	ARTICLE	IF	CITATIONS
55	Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 782-793.	6.7	89
56	Acute-phase serum amyloid A regulates tumor necrosis factor $\alpha$ and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. <i>Arthritis and Rheumatism</i> , 2012, 64, 1035-1045.	6.7	86
57	Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and Response. <i>Journal of Rheumatology</i> , 2014, 41, 1212-1217.	2.0	85
58	Exercise and Manual Physiotherapy Arthritis Research Trial (EMPART) for Osteoarthritis of the Hip: A Multicenter Randomized Controlled Trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2013, 94, 302-314.	0.9	84
59	Nucleotide Sequencing of Psoriatic Arthritis Tissue before and during Methotrexate Administration Reveals a Complex Inflammatory T Cell Infiltrate with Very Few Clones Exhibiting Features That Suggest They Drive the Inflammatory Process by Recognizing Autoantigens. <i>Journal of Immunology</i> , 2004, 172, 1935-1944.	0.8	81
60	Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. <i>Arthritis and Rheumatism</i> , 2006, 54, 3152-3162.	6.7	80
61	Increased synovial tissue NF- $\kappa$ B expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1781-1787.	6.7	77
62	Remission in psoriatic arthritis: is it possible and how can it be predicted?. <i>Arthritis Research and Therapy</i> , 2010, 12, R94.	3.5	77
63	Prospective study of the evolution of Raynaud's phenomenon. <i>American Journal of Medicine</i> , 1988, 84, 718-726.	1.5	74
64	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
65	Ultrasound guided injection of recalcitrant plantar fasciitis. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 383-383.	0.9	72
66	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
67	Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 3286-3295.	6.7	71
68	A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 225-230.	0.9	70
69	Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. <i>MAbs</i> , 2019, 11, 116-128.	5.2	70
70	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.9	68
71	Synovial membrane cellularity and vascularity.. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 511-515.	0.9	67
72	Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 726-729.	0.9	67

#	ARTICLE	IF	CITATIONS
73	Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1393-1398.	0.9	67
74	Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1795-1804.	6.7	66
75	Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 238-242.	0.9	65
76	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1882-1885.	0.9	64
77	Variants in <i>RUNX3</i> Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1224-1231.	6.7	63
78	Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 141.	3.5	62
79	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509.	6.7	60
80	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 358-362.	0.9	57
81	Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis. <i>American Journal of Cardiology</i> , 1993, 71, 1337-1340.	1.6	55
82	Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 corticotropin-releasing hormone receptor. <i>Arthritis and Rheumatism</i> , 2001, 44, 1761-1767.	6.7	54
83	Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?. <i>Arthritis Research</i> , 2004, 6, R563.	2.0	54
84	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020, 7, 553-580.	2.3	54
85	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.9	53
86	Responsiveness of physical function outcomes following physiotherapy intervention for osteoarthritis of the knee: an outcome comparison study. <i>Physiotherapy</i> , 2011, 97, 302-308.	0.4	52
87	Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 271-294.	6.5	52
88	Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis. <i>Pharmacoeconomics</i> , 2010, 28, 477-487.	3.3	51
89	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2277-2285.	2.0	51
90	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1774-1779.	0.9	51

#	ARTICLE	IF	CITATIONS
91	Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. <i>Molecular Immunology</i> , 2009, 46, 3345-3357.	2.2	50
92	Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 234-241.	0.9	50
93	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.4	50
94	Effects of 1-year anti-TNF- $\alpha$ therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2020, 39, 167-175.	2.2	50
95	Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. <i>Journal of Rheumatology</i> , 2007, 34, 620-2.	2.0	50
96	Modulation of Orphan Nuclear Receptor NURR1 Expression by Methotrexate in Human Inflammatory Joint Disease Involves Adenosine A2A Receptor-Mediated Responses. <i>Journal of Immunology</i> , 2005, 175, 555-565.	0.8	49
97	Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. <i>Rheumatology</i> , 2013, 52, 1572-1582.	1.9	47
98	Effects of targeted therapies on the bone in arthritides. <i>Autoimmunity Reviews</i> , 2017, 16, 313-320.	5.8	47
99	Lymphedema of the upper limb in patients with psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1993, 22, 350-356.	3.4	46
100	Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 493-499.	0.9	46
101	Identification of Naf1/ABIN-1 among TNF- $\alpha$ -induced expressed genes in human synoviocytes using oligonucleotide microarrays. <i>FEBS Letters</i> , 2003, 551, 8-12.	2.8	45
102	Early changes in serum type ii collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. <i>Arthritis and Rheumatism</i> , 2007, 56, 2919-2928.	6.7	45
103	Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 1998, 41, 180-182.	6.7	44
104	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
105	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.9	43
106	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	3.4	43
107	Quality of life, social support, and knowledge of disease in women with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 221-227.	6.7	42
108	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.0	42

#	ARTICLE	IF	CITATIONS
109	Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity. <i>Arthritis and Rheumatology</i> , 2018, 70, 396-407.	5.6	42
110	Filaggrin Null Alleles Are Not Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1878-1882.	0.7	41
111	Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study. <i>Arthritis Research and Therapy</i> , 2011, 13, R7.	3.5	41
112	Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. <i>Journal of Rheumatology</i> , 2009, 36, 1785-1791.	2.0	40
113	Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 706-714.	0.9	39
114	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1350-1354.	0.9	39
115	The Significance of Fat and Muscle Areas in the Lumbar Paraspinal Space. <i>Journal of Computer Assisted Tomography</i> , 1994, 18, 275-278.	0.9	38
116	Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design. <i>Journal of Rheumatology</i> , 2009, 36, 1792-1799.	2.0	38
117	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , 2019, 46, 1089-1096.	2.0	37
118	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2199-2203.	0.9	36
119	Vitamin D and its emerging role in immunopathology. <i>Clinical Rheumatology</i> , 2012, 31, 199-202.	2.2	36
120	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.0	36
121	Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) – Report of the OMERACT 10 PsA Special Interest Group. <i>Journal of Rheumatology</i> , 2011, 38, 1496-1501.	2.0	35
122	Development of a Disease Activity and Responder Index for Psoriatic Arthritis – Report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 782-791.	2.0	34
123	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418.	4.7	34
124	Enhanced Patient Involvement and the Need to Revise the Core Set – Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	2.0	34
125	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. <i>RMD Open</i> , 2018, 4, e000582.	3.8	34
126	Applying precision medicine to unmet clinical needs in psoriatic disease. <i>Nature Reviews Rheumatology</i> , 2020, 16, 609-627.	8.0	34



#	ARTICLE	IF	CITATIONS
127	Increased Expression of the Orphan Nuclear Receptor NURR1 in Psoriasis and Modulation following TNF- $\alpha$ Inhibition. <i>Journal of Investigative Dermatology</i> , 2008, 128, 300-310.	0.7	33
128	Vitamin D Deficiency: Subclinical and Clinical Consequences on Musculoskeletal Health. <i>Current Rheumatology Reports</i> , 2012, 14, 286-293.	4.7	33
129	Psoriatic arthritis: complexities, comorbidities and implications for the clinic. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 405-416.	3.0	33
130	Corticotropin-Releasing Hormone Signaling in Synovial Tissue Vascular Endothelium Is Mediated through the cAMP/CREB Pathway. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 119-130.	3.8	30
131	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter "Determining Validation Requirements. <i>Journal of Rheumatology</i> , 2016, 43, 208-213.	2.0	30
132	Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. <i>Arthritis Research and Therapy</i> , 2018, 20, 73.	3.5	30
133	Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. <i>Arthritis and Rheumatism</i> , 2004, 50, 1132-1145.	6.7	29
134	Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity. <i>American Journal of Pathology</i> , 2013, 183, 1243-1257.	3.8	29
135	Tumor necrosis factor- $\alpha$ in psoriasis and psoriatic arthritis: A clinical, genetic, and histopathologic perspective. <i>Current Rheumatology Reports</i> , 2004, 6, 292-298.	4.7	28
136	Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. <i>Arthritis Research and Therapy</i> , 2013, 15, R221.	3.5	28
137	Interleukin 15 Primes Natural Killer Cells to Kill via NKG2D and cPLA2 and This Pathway Is Active in Psoriatic Arthritis. <i>PLoS ONE</i> , 2013, 8, e76292.	2.5	28
138	Work Outcomes in Patients Who Stay at Work Despite Musculoskeletal Pain. <i>Journal of Occupational Rehabilitation</i> , 2018, 28, 559-567.	2.2	28
139	An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. <i>Drug Safety</i> , 2020, 43, 379-392.	3.2	28
140	Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans. <i>PLoS ONE</i> , 2013, 8, e66456.	2.5	27
141	Psoriatic arthritis: One or more diseases?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 435-450.	3.3	26
142	Constitutional trisomy 8 and Behçet syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2009, 149A, 982-986.	1.2	26
143	Composite Measures in Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 453-461.	2.0	26
144	Profound reduction in hospital admissions and musculoskeletal surgical procedures for rheumatoid arthritis with concurrent changes in clinical practice (1995-2010). <i>Rheumatology</i> , 2015, 54, 666-671.	1.9	26

#	ARTICLE	IF	CITATIONS
145	A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF treatment of psoriatic arthritis. <i>Proteomics - Clinical Applications</i> , 2016, 10, 645-662.	1.6	26
146	Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 158.	3.5	26
147	Periarticular Bone Gain at Proximal Interphalangeal Joints and Changes in Bone Turnover Markers in Response to Tumor Necrosis Factor Inhibitors in Rheumatoid and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 653-662.	2.0	25
148	Editorial: Emerging Evidence for Critical Involvement of the Interleukin-17 Pathway in Both Psoriasis and Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 1077-1080.	5.6	25
149	Advanced practice physiotherapy-led triage in Irish orthopaedic and rheumatology services: national data audit. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 181.	1.9	25
150	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	2.0	24
151	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 242.	3.5	24
152	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. <i>Rheumatology</i> , 2019, 58, 144-148.	1.9	24
153	Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 270-276.	0.8	24
154	Urease in the Gastric Mucosa and its Increase after a Meat Diet, Soya Bean Flour Diet or Urogastrone Injections. <i>Nature</i> , 1946, 158, 305-305.	27.8	22
155	Composite Measures in Psoriatic Arthritis: A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 540-545.	2.0	22
156	Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. <i>Journal of Rheumatology</i> , 2009, 36, 1769-1784.	2.0	21
157	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	3.4	21
158	Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discovery. <i>Proteomics - Clinical Applications</i> , 2016, 10, 691-698.	1.6	21
159	Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis. <i>Clinical Rheumatology</i> , 2015, 34, 1857-1865.	2.2	20
160	Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions. <i>Journal of Rheumatology</i> , 2016, 43, 463-464.	2.0	20
161	The Effect of Anterior Uveitis and Previously Undiagnosed Spondyloarthritis: Results from the DUET Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 1347-1354.	2.0	20
162	Early Origins of Psoriatic Arthritis: Clinical, Genetic and Molecular Biomarkers of Progression From Psoriasis to Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2021, 8, 723944.	2.6	20

#	ARTICLE	IF	CITATIONS
163	Biological biomarkers in psoriatic disease. A review. <i>Journal of Rheumatology</i> , 2008, 35, 1443-8.	2.0	20
164	Implications of the diversity of class I HLA associations in psoriatic arthritis. <i>Clinical Immunology</i> , 2016, 172, 29-33.	3.2	19
165	Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy. <i>Musculoskeletal Care</i> , 2017, 15, 23-35.	1.4	19
166	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology</i> , The, 2021, 3, e270-e283.	3.9	19
167	EFFECTS OF JOINT LAVAGE ON KNEE SYNOVITIS IN RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1985, 24, 6-10.	1.9	18
168	Synovial vascularity is increased in rheumatoid arthritis: Coment on the article by Stevens et al. <i>Arthritis and Rheumatism</i> , 1992, 35, 1540-1541.	6.7	18
169	Exercise and manual physiotherapy arthritis research trial (EMPART): a multicentre randomised controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 9.	1.9	18
170	Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 448-452.	2.0	18
171	Biomarkers in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 462-467.	2.0	18
172	Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1107-1113.	0.9	18
173	The many faces of psoriatic arthritis: their genetic determinism. <i>Rheumatology</i> , 2020, 59, i4-i9.	1.9	18
174	Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110140.	2.7	18
175	Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 401-4.	0.8	18
176	Peripheral joint involvement in psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S26-30.	0.8	18
177	Inhibition of PGE2 Production by Nimesulide Compared with Diclofenac in the Acutely Inflamed Joint of Patients with Arthritis. <i>Drugs</i> , 2003, 63, 31-36.	10.9	17
178	Temporal expression pattern of Duffy antigen in rheumatoid arthritis: Up-regulation in early disease. <i>Arthritis and Rheumatism</i> , 2006, 54, 2022-2026.	6.7	17
179	A qualitative study of work participation in early rheumatoid arthritis. <i>International Journal of Therapy and Rehabilitation</i> , 2010, 17, 24-33.	0.3	17
180	Psoriatic Arthritis Under a Proteomic Spotlight: Application of Novel Technologies to Advance Diagnosis and Management. <i>Current Rheumatology Reports</i> , 2015, 17, 35.	4.7	17

#	ARTICLE	IF	CITATIONS
181	A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1445-1452.	2.0	17
182	Advanced musculoskeletal physiotherapy practice: The patient journey and experience. <i>Musculoskeletal Science and Practice</i> , 2020, 45, 102077.	1.3	17
183	Pathogenetic Overview of Psoriatic Disease. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 7-10.	2.2	16
184	Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry. <i>Rheumatology</i> , 2016, 55, 891-896.	1.9	16
185	Remission in psoriatic arthritis—where are we now?. <i>Rheumatology</i> , 2018, 57, 1321-1331.	1.9	16
186	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	2.0	16
187	Spondyloarthropathy: disease at the crossroads of immunity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 949-967.	3.3	15
188	A Role for Type 1 $\beta$ Corticotropin-Releasing Hormone Receptors in Mediating Local Changes in Chronically Inflamed Tissue. <i>American Journal of Pathology</i> , 2007, 170, 1121-1133.	3.8	15
189	Investigation of IL1, VEGF, PPAR $\gamma$ and MEFV genes in psoriatic arthritis susceptibility: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 313-314.	0.9	15
190	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. <i>Arthritis and Rheumatology</i> , 2022, 74, 1535-1543.	5.6	15
191	Serum levels of tissue inhibitor of metalloproteinase-1 and periarticular bone loss in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 285-291.	2.2	14
192	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.0	14
193	Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 1997, 9, 295-301.	4.3	13
194	Preliminary observations on the influence of rheumatoid alpha-1-acid glycoprotein on collagen fibril formation. <i>Biomedical Chromatography</i> , 2002, 16, 332-342.	1.7	13
195	Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1206-1211.	2.0	13
196	Early interventions to promote work participation in people with regional musculoskeletal pain: a systematic review and meta-analysis. <i>Clinical Rehabilitation</i> , 2017, 31, 1466-1481.	2.2	13
197	Tuberculosis of the wrist. <i>Arthritis and Rheumatism</i> , 1999, 42, 2724-2726.	6.7	12
198	Differential Expression of NK Receptors CD94 and NKG2A by T Cells in Rheumatoid Arthritis Patients in Remission Compared to Active Disease. <i>PLoS ONE</i> , 2011, 6, e27182.	2.5	12

#	ARTICLE	IF	CITATIONS
199	Inflammatory back pain criteria perform well in subset of patients with active axial psoriatic arthritis but not among patients with established axial disease. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1003-1004.	0.9	12
200	Elevated CRP even at the first visit to a rheumatologist is associated with long-term poor outcomes in patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 2951-2961.	2.2	12
201	Poor long-term results from low-dose methotrexate therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1984, 27, 599-600.	6.7	11
202	Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2189-2192.	2.0	11
203	How Much Is Fatigue Explained by Standard Clinical Characteristics of Disease Activity in Patients With Inflammatory Arthritis? A Longitudinal Study. <i>Arthritis Care and Research</i> , 2014, 66, 1597-1603.	3.4	11
204	Opportunities and challenges in the treatment of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 440-452.	3.3	11
205	Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines. <i>Irish Journal of Medical Science</i> , 2019, 188, 169-172.	1.5	11
206	MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 330-336.	4.3	11
207	Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2). <i>Rheumatology and Therapy</i> , 2022, 9, 1017-1030.	2.3	11
208	The influence of $\alpha$ 1-acid glycoprotein on collagenase-3 activity in early rheumatoid arthritis. <i>Biomedical Chromatography</i> , 2003, 17, 361-364.	1.7	10
209	Clinical Image: Keratitis in reactive arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2522-2522.	6.7	10
210	Advanced musculoskeletal physiotherapy practice in Ireland: A National Survey. <i>Musculoskeletal Care</i> , 2018, 16, 425-432.	1.4	10
211	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020, 22, 78.	4.7	10
212	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
213	Multidisciplinary patient care in rheumatoid arthritis: evolving concepts in nursing practice. <i>Best Practice and Research in Clinical Rheumatology</i> , 1999, 13, 661-674.	3.3	9
214	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1021-1026.	2.0	9
215	Replication of a distinct psoriatic arthritis risk variant at the L23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1417-1418.	0.9	9
216	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021, 23, 94.	3.5	9

#	ARTICLE	IF	CITATIONS
217	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201674.	2.0	9
218	Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 81-91.	5.6	9
219	Disease Mechanisms in psoriasis and psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2001, 3, 419-427.	4.7	8
220	Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. <i>Rheumatology International</i> , 2010, 30, 1571-1580.	3.0	8
221	Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNF± therapy medication. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 11.	1.9	8
222	GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2196-2197.	2.0	8
223	A multidisciplinary approach to reproductive healthcare in women with rheumatic disease. <i>Irish Journal of Medical Science</i> , 2020, 189, 237-243.	1.5	8
224	Cardiovascular Comorbidities in Psoriatic Disease. <i>Rheumatology and Therapy</i> , 2020, 7, 5-17.	2.3	8
225	Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry. <i>Clinical Rheumatology</i> , 2008, 27, 763-766.	2.2	7
226	Modifications of Cardiovascular Risk Scores, But Not Standard Risk Scores, Improve Identification of Asymptomatic Coronary Artery Disease in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1329-1330.	2.0	7
227	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	0.9	7
228	Physiotherapist-Led Triage at a Rheumatology-Based Musculoskeletal Assessment Clinic: an 18-Month Service Evaluation of Activity and Outcomes. <i>ACR Open Rheumatology</i> , 2019, 1, 213-218.	2.1	7
229	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.7	7
230	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019, 95, 54-57.	2.0	7
231	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020, 96, 53-57.	2.0	7
232	The Impact of a Revised EQ-5D Population Scoring on Preference-Based Utility Scores in an Inflammatory Arthritis Cohort. <i>Value in Health</i> , 2011, 14, 921-927.	0.3	6
233	Apremilast: welcome advance in treatment of psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 385-386.	8.0	6
234	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1048-1051.	2.0	6

#	ARTICLE	IF	CITATIONS
235	Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?. <i>Rheumatology</i> , 2018, 57, 2053-2055.	1.9	6
236	Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 96, 19-24.	2.0	6
237	HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 123-124.	8.0	6
238	GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project. <i>Journal of Rheumatology</i> , 2014, 41, 1244-1248.	2.0	5
239	IL-6 blockade in psoriatic arthritis â€” a new therapeutic option?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 318-319.	8.0	5
240	Immunohistochemistry of the Inflamed Synovium. <i>Methods in Molecular Medicine</i> , 2007, 135, 47-63.	0.8	5
241	Psoriatic arthritisâ€™ an enthesopathy-based disorder? comment on the article by McGonagle et al. <i>Arthritis and Rheumatism</i> , 2000, 43, 712.	6.7	4
242	Application of the GRAPPA Psoriatic Arthritis Treatment Recommendations in Clinical Practice. <i>Current Rheumatology Reports</i> , 2010, 12, 264-271.	4.7	4
243	Pulmonary Fibrosis in Systemic Sclerosis. <i>Journal of Thoracic Imaging</i> , 2012, 27, 44-50.	1.5	4
244	5-year longitudinal study of clinical and patient-reported outcomes in acute anterior uveitis. <i>Eye</i> , 2021, 35, 651-658.	2.1	4
245	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. <i>Journal of Rheumatology</i> , 2021, 48, 1268-1271.	2.0	4
246	Psoriatic arthritis synovial histopathology: commentary on the article by Kruihof and colleagues. <i>Arthritis Research</i> , 2005, 7, 124.	2.0	3
247	Screening for arthritis in patients with psoriasis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 640-641.	8.0	3
248	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , 2016, 43, 979-985.	2.0	3
249	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020, 47, 796-808.	2.0	3
250	Bristol rheumatoid arthritis fatigue scale is valid in patients with psoriatic arthritis and is associated with overall severe disease and higher comorbidities. <i>Clinical Rheumatology</i> , 2020, 39, 1851-1858.	2.2	3
251	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 1021-1028.	3.0	3
252	Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201675.	2.0	3

#	ARTICLE	IF	CITATIONS
253	Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. BMC Musculoskeletal Disorders, 2021, 22, 817.	1.9	3
254	Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. Clinical Rheumatology, 2022, 41, 499-511.	2.2	3
255	GRAPPA 2017 Project Report. Journal of Rheumatology, 2018, 94, 48-51.	2.0	3
256	Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatology and Therapy, 0, , .	2.3	3
257	Inpatient and outpatient rehabilitation for patients with rheumatoid arthritis: a clinical and economic assessment. Journal of Medical Economics, 2007, 10, 515-528.	2.1	2
258	GRAPPA 2016 Project Report. Journal of Rheumatology, 2017, 44, 706-710.	2.0	2
259	Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 1272-1278.	2.0	2
260	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2021, , jrheum.201679.	2.0	2
261	Nicotinic acid inhibition of uricase. Irish Journal of Medical Science, 1969, 2, 531-534.	1.5	1
262	What are the spondyloarthropathies?. Best Practice and Research in Clinical Rheumatology, 2010, 24, 575-577.	3.3	1
263	O53.â€fPTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. Rheumatology, 2015, , .	1.9	1
264	AB0742â€...ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. , 2019, , .		1
265	SAT0395â€...RESPONSIVENESS AND CLINICAL TRIAL DISCRIMINATION OF SWOLLEN AND TENDER JOINT COUNTS FOR THE MEASUREMENT OF MSK DISEASE ACTIVITY IN PSORIATIC ARTHRITIS. , 2019, , .		1
266	Pathogenesis of Psoriatic Arthritis. , 2007, , 48-60.		1
267	Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis. Journal of Rheumatology, 2022, , jrheum.211321.	2.0	1
268	Osteoarthritis: 119. The Effectiveness of Exercise Therapy with and without Manual Therapy for Hip Osteoarthritis: A Multicentre Randomised Controlled Trial. Rheumatology, 2011, 50, iii87-iii90.	1.9	0
269	Biomarkers of Inflammatory Arthritis and Proteomics. , 2013, , .		0
270	Improving recognition of spondyloarthropathy in primary care: an unmet need. Annals of the Rheumatic Diseases, 2016, 75, e19-e19.	0.9	0



#	ARTICLE	IF	CITATIONS
271	Treatment of psoriatic arthritis. , 2016, , 85-99.		0
272	A new era for collaboration?. Rheumatology, 2018, 57, 775-776.	1.9	0
273	AB0440â€¦CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS. , 2019, , .		0
274	AB0763â€¦SAFETY OF ABATACEPT TREATMENT OVER 2 YEARS IN A PHASE III ACTIVE PSORIATIC ARTHRITIS RANDOMIZED TRIAL (ASTRAEA). , 2019, , .		0
275	Update: Atypical presentation of a midgut neuroendocrine tumor originally diagnosed as eosinophilic fasciitis. Neurology, 2020, 95, 695-697.	1.1	0
276	Corticosteroid-associated osteonecrosis of the femoral head: complete resolution on MRI with conservative treatment. BMJ Case Reports, 2009, 2009, bcr0820080673-bcr0820080673.	0.5	0
277	Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Journal of Rheumatology, 2022, , jrheum.211317.	2.0	0
278	GRAPPA 2020 Research Award Recipients. Journal of Rheumatology, 2022, , jrheum.211335.	2.0	0
279	Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects. Journal of Rheumatology, 2022, , jrheum.211320.	2.0	0
280	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. Journal of Rheumatology, 2022, , .	2.0	0